Interim results of a phase I/II, closed label, randomized pilot study for the safety and efficacy of TolaSure gel, 5% w/w targeting aggregated mutant keratin in severe epidermolysis bullosa simplex (TAMES)

TolaSure (BM-3103) - Biomendics

A.N. Johnson; K. McGuire; A. McCormick; K.E. Rieger; L. Broadwater; S. Jain; L. Perrone; J.M. Teng; J.Y. Tang; A.S. Chiou

Mar 4, 2023